The pill doesn’t work. For the general secretary of the CGT, Sophie Binet, the potential sale of Doliprane by Sanofi to an American investment fund is “the symbol of the total failure of Emmanuel Macron’s industrial policy”. “The scandal of the government’s industrial strategy is that it consists of giving full powers to multinationals,” continued Sophie Binet, this Tuesday morning on TF1. And here, in this case, we have a multinational which considers that it can make rain or shine. »
Sanofi has benefited from “a billion in research tax credits in 10 years” while “halving the workforce in France, particularly research jobs,” she said, calling for “conditioning of public aid to businesses” . The production cost of “each box of Doliprane is 15 cents. The selling price in pharmacies is 2 euros. So, we see that it is very profitable. Well, that’s not enough for Sanofi,” denounced the number 1 of the CGT.
The State “leaves the reins” to Sanofi
“The scandal is there, and we have a government, a State, which leaves the reins to Sanofi (…). Perhaps also because there is a very close proximity with the management of Sanofi and those in power,” she added. “The president of Sanofi (Frédéric Oudéa) is the husband of a former minister (of Sports Amélie Oudéa-Castéra, editor’s note). “It helps to have close relations with the macronie,” she said while refusing to imply the existence of personal interests in the matter.
The French pharmaceutical group announced at the end of last week that it had chosen the American investment fund CD&R to potentially cede control of its consumer health entity, Opella, which markets the drug Doliprane. A decision which raised serious concerns about the consequences for health sovereignty and the 250 jobs at the Lisieux factory, in Normandy.